BR112016013845A2 - Métodos de perfilagem de epítopos de células t, produção de composições de células t e tratamento de doenças - Google Patents

Métodos de perfilagem de epítopos de células t, produção de composições de células t e tratamento de doenças

Info

Publication number
BR112016013845A2
BR112016013845A2 BR112016013845A BR112016013845A BR112016013845A2 BR 112016013845 A2 BR112016013845 A2 BR 112016013845A2 BR 112016013845 A BR112016013845 A BR 112016013845A BR 112016013845 A BR112016013845 A BR 112016013845A BR 112016013845 A2 BR112016013845 A2 BR 112016013845A2
Authority
BR
Brazil
Prior art keywords
methods
diseases
cell
treatment
profiling
Prior art date
Application number
BR112016013845A
Other languages
English (en)
Inventor
Healey Don
West COLLISON Lauren
Original Assignee
Opexa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opexa Therapeutics Inc filed Critical Opexa Therapeutics Inc
Publication of BR112016013845A2 publication Critical patent/BR112016013845A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

MÉTODOS DE PERFILAGEM DE EPITOPOS DE CÉLULAS T, PRODUÇÃO DE COMPOSIÇÕES DE CÉLULAS T E TRATAMENTO DE DOENÇAS. A presente invenção refere-se um método de detecção de células T antígeno-específicas em uma amostra isolada de um indivíduo e mapeamento de epitopos imunoestimuladores do antígeno. Tais métodos podem ser usados em métodos para produzir composições de células T antígeno-específicas, por exemplo, para o tratamento de doenças como câncer, doenças infecciosas e distúrbios autoimunes.
BR112016013845A 2013-12-19 2014-12-19 Métodos de perfilagem de epítopos de células t, produção de composições de células t e tratamento de doenças BR112016013845A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361918570P 2013-12-19 2013-12-19
PCT/US2014/071571 WO2015095744A1 (en) 2013-12-19 2014-12-19 Methods of t cell epitope profiling, making t cell compositions, and treating diseases

Publications (1)

Publication Number Publication Date
BR112016013845A2 true BR112016013845A2 (pt) 2017-08-08

Family

ID=52478039

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016013845A BR112016013845A2 (pt) 2013-12-19 2014-12-19 Métodos de perfilagem de epítopos de células t, produção de composições de células t e tratamento de doenças

Country Status (10)

Country Link
US (1) US20160320408A1 (pt)
EP (1) EP3084435A1 (pt)
JP (1) JP2017505447A (pt)
CN (1) CN105992950A (pt)
AU (1) AU2014369008A1 (pt)
BR (1) BR112016013845A2 (pt)
CA (1) CA2934070A1 (pt)
IL (1) IL246202A0 (pt)
MX (1) MX2016007903A (pt)
WO (1) WO2015095744A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3260864B1 (en) * 2016-06-21 2024-08-07 Euroimmun Medizinische Labordiagnostika AG A diagnostic coincubation assay
CN110317246B (zh) * 2018-03-28 2022-08-02 深圳市安群生物工程有限公司 人mog抗原表位肽、抗原、抗体、应用及化学发光试剂盒
CN109136268A (zh) * 2018-09-30 2019-01-04 北京鼎成肽源生物技术有限公司 一种lrff细胞的构建方法
CN109337873A (zh) * 2018-09-30 2019-02-15 北京鼎成肽源生物技术有限公司 一种lrff细胞
CN113264991B (zh) * 2020-01-31 2023-05-16 上海桀蒙生物技术有限公司 病毒疫苗的制备方法及药物组合物
US20210338725A1 (en) * 2020-04-02 2021-11-04 Genocea Biosciences, Inc. Treatment methods
CN111773380A (zh) * 2020-04-26 2020-10-16 郑州大学第一附属医院 Plpp1在制备t细胞免疫肿瘤相关药剂中的应用
CN111751551B (zh) * 2020-06-08 2023-03-17 郑州大学第一附属医院 蛋白分子作为诊断肝硬化的生物标志物及其预后方法
CN113336862B (zh) * 2021-07-05 2022-03-01 广东省科学院动物研究所 一种抗多发性硬化的重组蛋白及其制备方法和用途
CN113481157B (zh) * 2021-07-21 2023-03-17 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞的优化制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
WO1988000970A2 (en) 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
WO1995004817A1 (en) 1993-08-06 1995-02-16 Cytel Corporation Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996027392A1 (en) 1995-03-08 1996-09-12 The Scripps Research Institute Antigen presenting system and methods for activation of t-cells
AU738538B2 (en) 1997-01-31 2001-09-20 Hemosol Inc. Method for the production of selected lymphocytes
WO2004050909A2 (en) * 2002-12-03 2004-06-17 Dartmouth College Method to measure a t cell response and its uses to qualify antigen-presenting cells
PL2420833T3 (pl) * 2006-05-05 2016-03-31 Opexa Therapeutics Szczepionka z komórek T

Also Published As

Publication number Publication date
US20160320408A1 (en) 2016-11-03
WO2015095744A1 (en) 2015-06-25
CA2934070A1 (en) 2015-06-25
MX2016007903A (es) 2016-12-16
AU2014369008A1 (en) 2016-07-07
EP3084435A1 (en) 2016-10-26
CN105992950A (zh) 2016-10-05
JP2017505447A (ja) 2017-02-16
IL246202A0 (en) 2016-07-31

Similar Documents

Publication Publication Date Title
BR112016013845A2 (pt) Métodos de perfilagem de epítopos de células t, produção de composições de células t e tratamento de doenças
MX2023001878A (es) Celulas modificadas geneticamente que comprenden un gen humano modificado de la region constante alfa del receptor de celulas t.
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
PH12018500965A1 (en) Methods and compositions for gene editing in hematopoietic stem cells
BR112017008696A2 (pt) métodos e composições para células exterminadoras naturais
CY1122956T1 (el) Αντισωματα εναντι αντιγονου 2 των δενδριτικων κυτταρων του αιματος και χρησεις αυτων
MX2019003489A (es) Moleculas del receptor de envolvimiento quimerico.
CO2017001561A2 (es) Anticuerpos anti tigit
NZ706189A (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
BR112017014031A2 (pt) n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado.
MX2019003616A (es) Celulas beta derivadas de celulas madre (sc-beta) y composiciones y metodos para generarlas.
SG10201803780UA (en) Methods and compositions for sustained immunotherapy
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
IN2014MN02518A (pt)
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
MX2019007492A (es) Composiciones de celulas t deficientes del receptor de celulas t.
EA201491470A1 (ru) Композиции фактора viii и способы получения и использования подобных
BR112013029834A8 (pt) vacinas individualizadas para câncer
BR112015021993A2 (pt) composições de cultura celular com antioxidantes e métodos para produção de polipeptídeo
MX363690B (es) Expansión de celulas madre adultas in vitro.
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
CY1118704T1 (el) Ανθρωπινος πληθυσμος βλαστοκυτταρων του τραχηλου της μητρας και χρησεις αυτου

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]